Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation

Circulation

Volumn 129, Issue 16, 2014, Pages 1688-1694

  Weitz, Jeffrey I ^a   Healey, Jeffrey S ^b   Skanes, Allan C ^c   Verma, Atul ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DISEASE MANAGEMENT; FEMALE; HUMANS; PREOPERATIVE CARE; WARFARIN;

EID: 84899080363     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.005376     Document Type: Article

References (21)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009;4:E1-E5.
3. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38.
4. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528-606.
5. Yau JW, Stafford AR, Liao P, Fredenburgh JC, Roberts R, Weitz JI. Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood. 2011;118:6667-6674.
6. Mardigyan V, Verma A, Birnie D, Guerra P, Redfearn D, Becker G, Champagne J, Sapp J, Gula L, Parkash R, Macle L, Crystal E, O'Hara G, Khaykin Y, Sturmer M, Veenhuyzen GD, Greiss I, Sarrazin JF, Mangat I, Novak P, Skanes A, Roux JF, Chauhan V, Hadjis T, Morillo CA, Essebag V. Anticoagulation Management Pre-and Post-AF ablation: A survey of Canadian centers. Can J Cardiol. 2012;29:219-223.
7. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084-2093.
8. DiBiase L, Bunkhardt JD, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Lakkireddy D, Verma A, Khaykin Y, Hongo R, Hao S, Beheiry S, Pelargonio G, Dello Russo A, Casella M, Santarelli P, Santangeli P, Wang P, Al-Ahmad A, Patel D, Themistoclakis S, Bonso A, Rossillo A, Corrado A, Raviele A, Cummings JI, Schweikert RA, Lewis WR, Natale A. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation. 2010;121:2550-2556.
9. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez J, Horton R, Gallinghouse GJ, Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, Rong B, Mohanty S, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoauglation management results from the "COMPARE" randomized trial. Heart Rhythm 2013; Abstract LB01-01.
10. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Heidbuchle H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126:343-348.
11. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59:1168-1174.
12. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y, Hirayama H, Murohara T. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:172-179.
13. Kim JS, She F, Jongnarangsin K, Chugh A, Latchamsetty R, Ghanbari H, Crawford T, Sinno M, Carrigan T, Kennedy R, Saint-Phard W, Yokokawa M, Good E, Bogun F, Pelosi F Jr, Morady F. Dabigatran vs. warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2012;10:483-489.
14. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, Lindsay BD, Wazni O. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460-466.
15. Arshad A, Buch E, Hamam I, Shaw RE, Musat D, Preminger M, Sichrovsky TC, Johnson C, Macias C, Mittal S, Shivkumar K, Mummel J, Steinberg JS. Comparative safety of anticoagulation strategies peri-ablation for atrial fibrillation: Data from a large multicenter study. Heart Rhythm 2013, Abstract #AB33-02.
16. Providencia R, Albenque JP, Combes S, Bouzeman A, Casteigt B, Combes N, Narayanan K, Marijon E, Boveda S. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014;100:324-335.
17. Lakkireddy DR, Reddy M, Swarup V, Baqdunes MW, Mansour M, Chaloub F, Ruskin J, DiBiase L, Vallakatti A, Janga P, Umbarger L, Sanchez J, Burkhardt D, Horton R, Reddy V, D'Aila A, Atkins D, Bommana S, Natale A. Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: A multicentre experience. Heart Rhythm 2013, Abstract #AB33-01.
18. Dillier R, Ammar S, Reents T, Pavaci H, Bulatti A, Schoen P, Kathan S, Hofmann M, Semmler V, Lemnerz C, Kolb C, Hessling G, Deisenhofter I. Safety and efficacy of continuous periprocedural rivaroxaban for patients undergoing catheter ablation procedures: A retrospective registry analysis. Heart Rhythm, 2013, Abstract #PO03-127.
19. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, Baheiry S, Ruskin J, Reddy V, Natale A. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective study. J Am Coll Cardiol. 2014;63:982-988.
20. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
21. Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost. 2012;10:1841-1848.